Patients with osteoarthritis exhibit significant gut microbiota dysbiosis and altered fecal metabolite profiles compared to healthy controls, revealing a 'gut-metabolism-immunity-joint' axis that may offer potential biomarkers for early diagnosis or therapeutic targets.
Key Findings
Results
OA patients showed significant gut microbiota dysbiosis characterized by reductions in beneficial bacterial groups and increases in potentially harmful taxa compared to healthy controls.
55 OA patients from the affiliated hospital of Anhui Medical University were compared with 55 healthy controls in a cross-sectional design
Beneficial bacterial groups reduced in OA included Clostridiales, Lactobacillales, Bacilli, and Actinobacteria
Bacterial groups increased in OA included Bacteroidaceae and Burkholderiales
Gut microbiota profiling was performed using 16S rRNA (V4-V5) sequencing
Results
Fecal metabolomic analysis revealed enrichment of specific metabolic pathways in OA patients, including beta-alanine metabolism and pyrimidine metabolism.
Metabolomics was conducted using POS/NEG dual-ion-mode untargeted fecal metabolomics
Beta-alanine metabolism and pyrimidine metabolism pathways were among those enriched in OA patients
The metabolomic findings were interpreted in the context of a 'gut-metabolism-immunity-joint' axis
Differential metabolites were identified as potential biomarkers for early diagnosis or therapeutic targets
Results
Reductions in Actinobacteria were positively correlated with downregulation of indole-3-acetic acid, a metabolite considered to have beneficial effects.
Indole-3-acetic acid was identified as a downregulated metabolite in OA patients
The reduction in Actinobacteria showed a positive correlation with decreased indole-3-acetic acid levels
This association illustrates a direct link between specific microbial changes and host metabolic alterations in OA
Results
Reductions in Bacilli and Lactobacillales were associated with dual loss of luteolin and D-tryptophan in OA patients.
Both luteolin and D-tryptophan were identified as downregulated metabolites in OA
Bacilli and Lactobacillales were both reduced in OA patients and linked to these metabolite losses
This finding further supports microbiota-metabolite co-alterations in OA pathophysiology
Conclusions
The study identified significant alterations in both gut microbiota and fecal metabolites in OA patients compared to healthy individuals, supporting the role of gut dysbiosis in OA pathogenesis.
The study investigated the 'gut-metabolism-immunity-joint' axis as a framework for understanding OA
OA pathogenesis was described as rooted in metabolic irregularities, synovitis, immune system responses, and body-wide inflammation
Findings offer 'new insights for future personalized interventions' according to the authors
The identified differential metabolites 'hold promise as potential biomarkers for early diagnosis or therapeutic targets'
What This Means
This research suggests that people with osteoarthritis (OA), a common joint disease, have notably different gut bacteria and gut-produced chemical compounds compared to healthy people. The study compared 55 OA patients with 55 healthy individuals in China, analyzing stool samples for both bacterial composition and metabolites (small molecules produced by bacteria and the body). OA patients had fewer 'beneficial' bacteria such as Lactobacillales and Actinobacteria, and more of certain other bacterial groups like Bacteroidaceae, a pattern known as gut dysbiosis.
The changes in gut bacteria were linked to changes in specific metabolites. For example, lower levels of Actinobacteria were associated with lower levels of indole-3-acetic acid, a compound thought to be beneficial, while reductions in Lactobacillales and Bacilli were tied to lower levels of luteolin and D-tryptophan. Metabolic pathways related to beta-alanine and pyrimidine metabolism were also found to be altered in OA patients. These findings suggest a connected 'gut-metabolism-immunity-joint' pathway that may contribute to joint inflammation and damage in OA.
This research suggests that the gut microbiome may play a meaningful role in osteoarthritis beyond just the joints themselves. The specific bacterial and metabolite differences identified could potentially serve as early diagnostic markers or future treatment targets, potentially opening the door to personalized therapies that target the gut microbiome in OA patients. However, as a cross-sectional study, it cannot establish whether gut dysbiosis causes OA or results from it, and further research would be needed to confirm these findings.
Zhou Q, Wang J, Zhang L, He Y, Liu H, Cao Y, et al.. (2026). Fecal microbiota and metabolite profiles in patients with osteoarthritis: a cross-sectional study.. Frontiers in cellular and infection microbiology. https://doi.org/10.3389/fcimb.2026.1816705